HomeAI · summaries
Storia in 10 fonti
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to curb the trend before the U.S. loses key biotechnology capabilities. During these discussions, it was only fitting that Pfizer struck an eye-popping development deal with Innovent on 12 cancer meds. And Astellas, facing a key patent cliff, is telling investors how it plans to adapt. Plus more.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercebiotech.com
As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block those deals have gotten louder. | Amid an…
- ·
fiercepharma.com
Cancer is changing. Is pharma marketing changing with it?
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report examines key trends, gaps in care, and how data and…
- ·
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster…
- ·
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets…
- ·
Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
With China's growing dominance in the biopharma R&D sector, a collection of g | A group of over 20 global pharma leaders met with Japan's Prime Minister Sanae Takaichi to address…
- ·
Continuous Manufacturing Strategies for Scalable mAb Production
Explore how continuous manufacturing strategies can support more scalable, efficient, and cost-effective mAb production. Download this free whitepaper for insights into process…
- ·
morningstar.com
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
- ·
biopharmadive.com
Pfizer, Innovent strike $10B cancer drug deal
Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.
- ·
thehindubusinessline.com
Pfizer inks up to $10.5 billion deal with China’s Innovent Biologics
Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer drugs.
- ·
asia.nikkei.com
China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn
Biotech firm says global expansion still under development
- ·
cnbc.com
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
- ·
scmp.com
China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials
The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.
- ·
startmag.it
L'accordo con Innovent Biologics fa tenere a Pfizer un piede negli Usa e l'altro in Cina - Startmag
La collaborazione tra Pfizer e Innovent riguarda un portafoglio di 12 programmi oncologici, composto da 8 asset in fase iniziale
- ·
Pharma urged to modernize patient support as young adult cancer rates rise
Pharma companies need to strengthen and modernize patient support programs to reflect rising rates of cancer in adults aged 18 to 49 years, an Omnicom Health report found. |…
- ·
endpoints.news
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and…
- ·
Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
In the U.S., many top brand-name drugs continue to get more expensive with age, while the same medicines often get cheaper in peer countries, according to an AARP Public Policy…
- ·
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed assets gain more attention from biopharma…